DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR INLYTA
Clinical Trials for Inlyta
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00700258 | Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] | Recruiting | Pfizer | N/A | 2013-01-01 | The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use |
| NCT01321437 | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | Active, not recruiting | Pfizer | Phase 2 | 2011-12-01 | The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma. |
| NCT01321437 | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | Active, not recruiting | University of California, Irvine | Phase 2 | 2011-12-01 | The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma. |
| NCT01529138 | Study of Axitinib and Temsirolimus in Solid Tumors | Completed | Pfizer | Phase 1 | 2011-10-01 | This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial. |
| NCT01529138 | Study of Axitinib and Temsirolimus in Solid Tumors | Completed | Emory University | Phase 1 | 2011-10-01 | This study is being done to determine the highest safe dose of the combination of temsirolimus and axitinib; to learn the side effects when these drugs are given together; and to determine how the patient's disease responds to treatment. The combination of the drugs temsirolimus and axitinib has not been studied before so it is unknown whether this treatment will have any benefit in the patient's cancer. Temsirolimus is commercially available and approved for treatment of some types of kidney cancer. Axitinib has been tested in several diseases but it is not yet commercially available for the treatment of any cancer in the United States. The combination of temsirolimus and axitinib is not approved for treatment of any cancer outside of a clinical trial. |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | Terminated | National Cancer Institute (NCI) | Phase 2 | 2012-01-01 | This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Inlyta
Condition Name
Condition MeSH
Clinical Trial Locations for Inlyta
Trials by Country
Clinical Trial Progress for Inlyta
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Inlyta
Sponsor Name
